[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Yang HK, Yu HG: Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease. Korean J Ophthalmol; 2009 Dec;23(4):325-8
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease.
  • We describe a case of bilateral exudative retinal detachment associated with prodromal symptoms simulating the presentation of acute Vogt-Koyanagi-Harada disease that was eventually diagnosed as acute lymphoblastic leukemia.
  • A clinical diagnosis of incomplete type Vogt-Koyanagi-Harada disease was considered.
  • However, complete blood cell count showed a marked increase in the number of white blood cells and bone marrow examination revealed precursor B cell lymphoblastic leukemia.
  • The patient started on induction chemotherapy.
  • Bilateral exudative retinal detachment associated with neurologic and auditory abnormalities may be a presenting sign of acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / etiology. Uveomeningoencephalitic Syndrome / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fluorescein Angiography. Follow-Up Studies. Fundus Oculi. Humans. Male. Tomography, Optical Coherence. Visual Acuity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kaohsiung J Med Sci. 2001 Mar;17(3):150-5 [11486647.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):691-9 [12447107.001]
  • [Cites] Leuk Res. 2003 Jun;27(6):557-9 [12648516.001]
  • [Cites] Am J Ophthalmol. 1979 May;87(5):698-702 [443342.001]
  • [Cites] Ann Ophthalmol. 1979 Dec;11(12):1867-72 [299244.001]
  • [Cites] Am J Ophthalmol. 1987 Oct 15;104(4):364-72 [3661646.001]
  • [Cites] Retina. 1989;9(2):110-4 [2772418.001]
  • [Cites] Am J Ophthalmol. 1990 Apr 15;109(4):436-44 [2330946.001]
  • [Cites] Am J Ophthalmol. 1996 Jul;122(1):58-66 [8659599.001]
  • [Cites] Surv Ophthalmol. 1964 Oct;9:467-73 [14199728.001]
  • [Cites] Eur J Ophthalmol. 2005 Mar-Apr;15(2):284-6 [15812775.001]
  • [Cites] Retina. 2006 Jul-Aug;26(6):710-2 [16829822.001]
  • [Cites] Am J Ophthalmol. 2007 Aug;144(2):260-5 [17533104.001]
  • [Cites] Curr Eye Res. 2008 Jul;33(7):517-23 [18600484.001]
  • [Cites] Retina. 2003 Dec;23(6):820-46; quiz 895-6 [14707834.001]
  • [Cites] Acta Haematol. 2000;104(1):46-9 [11111123.001]
  • [Cites] Am J Ophthalmol. 2001 May;131(5):647-52 [11336942.001]
  • [Cites] Retina. 2001;21(3):237-42 [11421013.001]
  • (PMID = 20046700.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2789964
  • [Keywords] NOTNLM ; Exudative retinal detachment / Leukemia / Vogt-Koyanagi-Harada disease
  •  go-up   go-down


2. Zhioua R, Boussen I, Malek I, Ouertani A: [Acute lymphoblastic leukemia and vitreous infiltration. A case study]. J Fr Ophtalmol; 2001 Feb;24(2):180-2
MedlinePlus Health Information. consumer health - Eye Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia and vitreous infiltration. A case study].
  • The infiltration of the vitreous by acute lymphoblastic leukemia is rare.
  • We report the case of a 5-year-old child with acute type-2 lymphoblastic leukemia who had a bilateral dense cellular infiltration resulting in significant vision loss in both eyes with the child counting her fingers at a distance of 20cm.
  • Because the vitreous was not cleared by chemotherapy, we performed a bilateral vitrectomy.
  • [MeSH-major] Eye Diseases / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Vitreous Body
  • [MeSH-minor] Child, Preschool. Female. Follow-Up Studies. Humans. Time Factors. Visual Acuity. Vitrectomy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11240492.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Huck K, Laws HJ, Meisel R, Traeger A, Bernbeck B, Schonberger S, Stackelberg VA, Pape H, Dilloo D: Three cases of renal relapse after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia. Haematologica; 2006 May;91(5 Suppl):ECR07
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of renal relapse after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia.
  • Isolated renal relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) in children with acute lymphoblastic leukemia (ALL) is a rare condition.
  • Here we report on three young boys with relapsed B-precursor ALL, who underwent alloHSCT from HLA-identical siblings and suffered a histopathologically proven isolated unilateral renal relapse (two patients) or a combined renal and testicular relapse (one patient) 6, 10 and 12 months post alloHSCT.
  • In all patients at the time of relapse bone marrow showed complete remission with complete donor hematopoiesis.
  • They all received total body irradiation with partial shielding of the kidneys as part of their conditioning therapy, such that renal shielding could be an explanation for the observed accumulation of renal relapses.
  • Moreover, during the past few years so called immune privilege has been postulated for frequent relapse sites such as the CNS, the testicles and the anterior chamber of the eye.
  • Due to these observations we advocate sufficient treatment of the kidneys during conditioning therapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Kidney / pathology. Leukemic Infiltration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dendritic Cells / transplantation. Disease Progression. Etoposide / therapeutic use. Fatal Outcome. Humans. Immunotherapy. Leukocyte Transfusion. Magnetic Resonance Imaging. Male. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / surgery. Radiation Protection. Recurrence. Salvage Therapy. Tomography, X-Ray Computed. Transplantation Conditioning / adverse effects. Transplantation, Homologous. Whole-Body Irradiation / adverse effects


Advertisement
4. Im SK, Yoon KC: Corneal perforation with preseptal cellulitis in a patient with acute lymphocytic leukemia. J Korean Med Sci; 2010 Aug;25(8):1251-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 17-yr-old female patient who was undergoing combination chemotherapy for ALL was referred due to upper lid swelling and pain in the right eye for 2 days.
  • Visual acuity in the right eye was 20/20.
  • Computed tomography showed a finding of preseptal cellulitis.
  • Corneal melting and perforation with iris prolapse were detected in the right eye on the 16th day.
  • Seven months after surgery, visual acuity in the right eye was 20/300, and the corneal graft was stable.
  • [MeSH-major] Cellulitis / diagnosis. Corneal Perforation / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Corneal Transplantation. Drug Therapy, Combination. Female. Humans. Serratia marcescens / isolation & purification. Tomography, X-Ray Computed. Visual Acuity

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Immun. 1981 Sep;33(3):927-32 [7026449.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1359-73 [8839540.001]
  • [Cites] Am J Ophthalmol. 1998 Apr;125(4):493-501 [9559735.001]
  • [Cites] J Fr Ophtalmol. 1999 Aug-Sep;22(7):753-4 [10510754.001]
  • [Cites] Surv Ophthalmol. 2006 Jan-Feb;51(1):19-40 [16414359.001]
  • [Cites] Surv Ophthalmol. 2001 Nov-Dec;46(3):259-68 [11738433.001]
  • [Cites] Eye (Lond). 2003 Jul;17(5):677-8 [12855993.001]
  • (PMID = 20676345.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC2908803
  • [Keywords] NOTNLM ; Corneal Perforation / Drug Therapy / Precursor Cell Lymphoblastic Leukemia-Lymphoma / Preseptal Cellulitis / Serratia marcescens
  •  go-up   go-down


5. Somervaille TC, Hann IM, Harrison G, Eden TO, Gibson BE, Hill FG, Mitchell C, Kinsey SE, Vora AJ, Lilleyman JS, MRC Childhood Leukaemia Working Party: Intraocular relapse of childhood acute lymphoblastic leukaemia. Br J Haematol; 2003 Apr;121(2):280-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraocular relapse of childhood acute lymphoblastic leukaemia.
  • Relapse of childhood acute lymphoblastic leukaemia (ALL) involving the eye is a rare but challenging problem.
  • Twenty cases occurred in patients treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia XI and ALL97 trials between 1991 and 2001, representing 2.2% of ALL relapses.
  • All patients with intraocular disease at first relapse were treated with both chemotherapy and radiotherapy, but the doses and protocols used varied.
  • All 11 children that were treated with a full chemotherapy relapse protocol, together with local radiotherapy have survived.
  • Patients treated with chemotherapy of shorter duration and intensity, despite radiotherapy and/or bone marrow transplantation, did poorly with only one survivor, currently in chronic relapse.
  • Consequently, we suggest that children with eye relapse of ALL be treated with an intensive relapse chemotherapy protocol with local ocular radiotherapy, whether the relapse occurs in isolation or in combination with relapse at another site.
  • [MeSH-major] Eye / pathology. Leukemic Infiltration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / pathology. Central Nervous System / pathology. Child. Child, Preschool. Combined Modality Therapy. Databases, Factual. Female. Follow-Up Studies. Great Britain. Humans. Infant. Male. Recurrence. Survival Rate

  • MedlinePlus Health Information. consumer health - Eye Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694250.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


6. Patel SV, Herman DC, Anderson PM, Al-Zein NJ, Buettner H: Iris and anterior chamber involvement in acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2003 Aug;25(8):653-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iris and anterior chamber involvement in acute lymphoblastic leukemia.
  • The authors describe a 6-year-old child, with a history of acute lymphoblastic leukemia, who presented with leukemic infiltration of the anterior segment of one eye mimicking anterior uveitis.
  • After tissue diagnosis, administration of radiation therapy to the affected eye resulted in dramatic improvement of the condition.
  • In the absence of systemic relapse, local radiation therapy without chemotherapy is highly effective, although the prognosis in these patients may be guarded.
  • [MeSH-major] Iris Neoplasms / diagnosis. Iris Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Uveitis / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Male. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12902923.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Charif CM, Loughzail K, Benkirane N, Berraho A: [Ocular relapse of acute lymphoblastic leukemia]. Bull Soc Belge Ophtalmol; 2002;(286):27-30
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular relapse of acute lymphoblastic leukemia].
  • A five years old child with acute lymphoblastic leukemia presented after 30 months of treatment a bilateral hypopyon.
  • The treatment included the association of topical corticosteroids, chemotherapy and radiotherapy.
  • We remind the different clinical aspects of leukemic invasion of the anterior segment and the therapeutic methods for this relapse.
  • [MeSH-major] Anterior Chamber / pathology. Eye Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Administration, Topical. Adrenal Cortex Hormones / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Fatal Outcome. Humans. Methotrexate / administration & dosage. Paracentesis. Radiotherapy, Adjuvant. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12564314.001).
  • [ISSN] 0081-0746
  • [Journal-full-title] Bulletin de la Société belge d'ophtalmologie
  • [ISO-abbreviation] Bull Soc Belge Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Malik R, Shah A, Greaney MJ, Dick AD: Bilateral serous macular detachment as a presenting feature of acute lymphoblastic leukemia. Eur J Ophthalmol; 2005 Mar-Apr;15(2):284-6
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral serous macular detachment as a presenting feature of acute lymphoblastic leukemia.
  • PURPOSE: To report a case of bilateral serous maculopathy as an initial sign of acute lymphoblastic leukaemia in children.
  • A bone marrow aspirate revealed the presence of leukemic blasts and a diagnosis of acute lymphoblastic leukaemia was made.
  • Her maculopathy completely resolved following systemic chemotherapy.
  • CONCLUSIONS: Prompt recognition of disease led to early systemic treatment and restoration of visual function.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / diagnosis
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Fluorescein Angiography. Humans. Vision Disorders / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812775.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Landau H, Lamanna N: Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. Curr Hematol Malig Rep; 2006 Sep;1(3):171-9
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults.
  • Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic and prognostic subgroups.
  • The treatment of adults with ALL has evolved largely from the therapy developed for childhood ALL and, despite differences across regimens, can be broadly classified as including induction, consolidation, maintenance, and central nervous system prophylaxis.
  • This article reviews the classification, prognostic features, current treatment programs, and new advances as applied to adult patients with newly diagnosed ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / classification. Burkitt Lymphoma / therapy. Central Nervous System / pathology. Child. Clinical Trials as Topic. Cranial Irradiation. Eye / pathology. Hematopoietic Stem Cell Transplantation. Humans. Immunophenotyping. Incidence. Leukemic Infiltration / drug therapy. Leukemic Infiltration / prevention & control. Leukemic Infiltration / radiotherapy. Lymphocyte Subsets / pathology. Male. Neoplasm, Residual. Prognosis. Remission Induction. Testis / pathology. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):40-6 [14695849.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] J Clin Oncol. 1983 Aug;1(8):462-70 [6583321.001]
  • [Cites] Lancet. 1996 Jun 29;347(9018):1783-8 [8667921.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:178-81 [1578927.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2480-5 [8823326.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Ann Intern Med. 1995 Sep 15;123(6):428-31 [7639442.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1508-16 [10735899.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3707-21 [11054444.001]
  • [Cites] Blood. 1980 Feb;55(2):199-204 [6928104.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1014-30 [3163722.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2580-7 [7989932.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • [Cites] Blood. 1988 Nov;72(5):1784-9 [3052630.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2032-5 [15483674.001]
  • [Cites] Blood. 1984 Jul;64(1):38-47 [6375764.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):476-82 [9053468.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Oncol Rep. 2005 Sep;7(5):323-32 [16091192.001]
  • [Cites] Blood. 1984 Jul;64(1):267-74 [6375760.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):64-6 [3296208.001]
  • [Cites] Jpn J Clin Oncol. 1993 Apr;23(2):85-97 [7685836.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5251-6 [8652840.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1811-22 [11753600.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4014-22 [11600602.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1603-12 [8068949.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Leukemia. 1991 May;5(5):425-31 [2033963.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4695-700 [12586618.001]
  • [Cites] Leukemia. 2005 May;19(5):734-40 [15789069.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1509-16 [16034462.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):184-8 [12525508.001]
  • (PMID = 20425348.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


10. Pojda-Wilczek D, Pojda SM, Zatorska B, Herba E, Jedrzejewski W, Janik-Moszant A, Bubała H: [Acute endophthalmitis of 15-year old boy in the course of acute lymphoblastic leukemia--part I]. Klin Oczna; 2004;106(6):788-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute endophthalmitis of 15-year old boy in the course of acute lymphoblastic leukemia--part I].
  • PURPOSE: The aim of this study is to present dramatic ocular manifestation of acute lymphoblastic leukemia.
  • MATERIAL AND METHODS: 15-year old boy was hospitalized due to acute leukemia at the Department and Clinic of Pediatric Hematology and was referred to ophthalmologist because of strong pain and decreased visual acuity of the left eye.
  • After one week of local anti-inflammatory treatment the eye became painless with little deep injection only.
  • Simultaneously causal treatment of basic disease was continued.
  • The patients require local symptomatic and general causal treatment in cooperation of ophthalmologist with hematologist.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endophthalmitis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787183.001).
  • [ISSN] 0023-2157
  • [Journal-full-title] Klinika oczna
  • [ISO-abbreviation] Klin Oczna
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


11. Nishio H, Sakakibara-Kawamura K, Suzuki T, Utsumi T, Kinoshita S: [An autopsy case of Ph1--positive acute lymphoblastic leukemia with disseminated infection of Fusarium solani]. Kansenshogaku Zasshi; 2002 Jan;76(1):67-71
MedlinePlus Health Information. consumer health - Fungal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsy case of Ph1--positive acute lymphoblastic leukemia with disseminated infection of Fusarium solani].
  • A 56-year-old woman with Ph1--Positive acute Lymphoblastic Leukemia was admitted to our hospital for induction chemotherapy in June 1999.
  • The patient was presented with a central scotoma of left eye during treatment course and was given diagnosis of endophthalmitis.
  • Thereafter she also developed skin induration and suffered from serious pneumonia.
  • Autopsy was performed, and its specimen revealed the disseminated infection of Fusarium solani (lung, eye, heart, kidney and skin).
  • [MeSH-major] Fusarium. Mycoses / etiology. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11852477.001).
  • [ISSN] 0387-5911
  • [Journal-full-title] Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases
  • [ISO-abbreviation] Kansenshogaku Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Raparia K, Chang CC, Chévez-Barrios P: Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens. Arch Pathol Lab Med; 2009 Aug;133(8):1233-7
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens.
  • CONTEXT: Diagnosis and classification of primary intraocular lymphoma can be challenging because of the sparse cellularity of the vitreous specimens.
  • OBJECTIVE: To classify and clinically correlate intraocular lymphoma according to the World Health Organization (WHO) classification by using vitrectomy specimens.
  • DESIGN: Clinical history, cytologic preparations, flow cytometry reports, and outcome of 16 patients diagnosed with intraocular lymphoma were reviewed.
  • The cases included 9 primary diffuse large B-cell lymphomas of the CNS type; 2 diffuse large B-cell lymphomas, not otherwise specified; 1 extranodal, low-grade, marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT); 1 precursor B-lymphoblastic lymphoma; and 3 peripheral T-cell lymphomas, not otherwise specified.
  • Of note, all 11 cases of diffuse large B-cell lymphoma were CD10-.
  • All the patients received systemic chemotherapy and radiation therapy.
  • CONCLUSIONS: Intraocular lymphoma cases can be adequately classified according to the WHO classification.
  • Diffuse large B-cell lymphoma, CD10- and most likely of non-germinal center B-cell-like subgroup, is the most common subtype of non-Hodgkin lymphoma in this site, in contrast to ocular adnexal lymphoma for which MALT lymphoma is the most common subtype.
  • [MeSH-major] Eye Neoplasms / diagnosis. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis. Vitrectomy / methods. Vitreous Body / pathology
  • [MeSH-minor] Adult. Aged. Cytodiagnosis / methods. Female. Flow Cytometry. Humans. Lymphoma, B-Cell, Marginal Zone / classification. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Retrospective Studies. Survival Rate. Texas / epidemiology. World Health Organization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653716.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R, Kuwana M, Tsubota K, Ikeda Y, Oguchi Y: Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant; 2003 Apr;31(7):579-83
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease.
  • We investigated the efficacy and safety of autologous serum eye drops for the treatment of severe dry eye after allogeneic haematopoietic stem cell transplantation (SCT).
  • A total of 14 patients (four males and 10 females; median age, 31.0 years) with severe dry eye associated with chronic graft-versus-host disease (cGVHD) were enrolled in this study.
  • All patients were refractory to treatment with conventional artificial tears.
  • Autologous serum eye drops, a solution made of 20% autologous serum in sterile saline, were applied 10 times per eye per day.
  • After 4 weeks of treatment, significant improvement was observed in both complaint scores (from 33.7+/-12.3 to 23.6+/-10.6 points; P<0.01) and fluorescein scores (from 5.8+/-2.0 to 2.4+/-0.9 points; P<0.005).
  • Significant improvements were observed also in rose-bengal staining and tear break-up time.
  • In seven of the 14 patients, the responses were maintained for 6-41 months (median:19.4+/-8.3 months), while six of the other seven patients required treatment with punctal plugs in addition to autologous serum eye drops.
  • One of these other seven patients developed eczema around the eyelids, after which the treatment was discontinued.
  • We conclude that autologous serum eye drops are safe and effective for treating severe dry eye associated with cGVHD and that more efficient control of dry eye may be achieved by the combined use of autologous serum eye drops with punctal plugs.
  • [MeSH-major] Blood Proteins / administration & dosage. Dry Eye Syndromes / drug therapy. Dry Eye Syndromes / etiology. Graft vs Host Disease / complications. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • [MeSH-minor] Adult. Chronic Disease. Female. Humans. Male. Myelodysplastic Syndromes / therapy. Ophthalmic Solutions / administration & dosage. Ophthalmic Solutions / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692625.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Ophthalmic Solutions
  •  go-up   go-down


14. Hurtado-Sarrió M, Duch-Samper A, Taboada-Esteve J, Martínez-Dominguez JA, Senent-Peris ML, Menezo-Rozalén JL: Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib. Am J Ophthalmol; 2005 Apr;139(4):723-4
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.
  • PURPOSE: Anterior chamber involvement is unusual in patients with acute lymphoblastic leukemia (ALL) and has never been described in the setting of Ph+ (Philadelphia chromosome-positive) ALL.
  • RESULTS: Although there was no evidence of leukemia in the blood or bone marrow samples, aqueous fluid cytology identified Ph+ positive lymphoblastic leukemic cells.
  • CONCLUSIONS: The patient had developed anterior chamber infiltration without hematological relapse while treated with imatinib.
  • [MeSH-major] Anterior Chamber / pathology. Antineoplastic Agents / therapeutic use. Eye Neoplasms / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemic Infiltration / pathology. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Aqueous Humor / cytology. Benzamides. Female. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Middle Aged. Philadelphia Chromosome. Remission Induction. Uveitis, Anterior / diagnosis


15. Pojda-Wilczek D, Pojda SM, Herba E, Makowiecka-Obidzińska K: [Acute endophthalmitis of 15-year old boy in the course of acute lymphoblastic leukemia. Part II--Electrophysiological examinations]. Klin Oczna; 2004;106(6):791-4
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute endophthalmitis of 15-year old boy in the course of acute lymphoblastic leukemia. Part II--Electrophysiological examinations].
  • In the eye with retinal infiltration abnormal EOG was present a few months earlier than pigment epithelium destruction was seen in ocular fundus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endophthalmitis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787184.001).
  • [ISSN] 0023-2157
  • [Journal-full-title] Klinika oczna
  • [ISO-abbreviation] Klin Oczna
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


16. Rutar T, Cockerham KP: Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am J Ophthalmol; 2006 Jul;142(1):187-188
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report on the successful treatment of periorbital zygomycosis (mucormycosis) with posaconazole, a broad-spectrum oral antifungal available for compassionate use.
  • RESULTS: A 22-year-old male undergoing induction chemotherapy for acute lymphoblastic leukemia presented with periorbital cellulitis attributable to Rhizopus.
  • He took posaconazole for five months while undergoing additional cycles of chemotherapy.
  • CONCLUSIONS: Drug toxicities can limit the use of amphotericin in some patients with zygomycosis.
  • Posaconazole shows promise as an alternative antifungal agent in the treatment of periorbital zygomycosis.
  • [MeSH-major] Antifungal Agents / therapeutic use. Eye Infections, Fungal / drug therapy. Mucormycosis / drug therapy. Orbital Diseases / drug therapy. Rhizopus / isolation & purification. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Humans. Male. Microbial Sensitivity Tests. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Zygomycosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16815283.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Triazoles; 6TK1G07BHZ / posaconazole
  •  go-up   go-down


17. Chawla B, Agarwal P, Tandon R, Titiyal JS: Peripheral ulcerative keratitis with bilateral optic nerve involvement as an initial presentation of acute lymphocytic leukemia in an adult. Int Ophthalmol; 2009 Feb;29(1):53-5
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 24-year-old patient presented with complaints of pain, redness, and watering in the right eye since 15 days along with progressive decrease of vision since 3 months, leading to bilateral blindness.
  • Examination of the right eye revealed a PUK and adjacent localized scleritis.
  • Head computed tomography was normal.
  • For sclerokeratitis, the patient was recommended topical steroids along with adjuvant therapy.
  • She was referred to the oncology services for management of leukemia and was treated with chemotherapy.
  • Early diagnosis and prompt management may save the patient from blindness.
  • [MeSH-major] Corneal Ulcer / diagnosis. Optic Nerve Diseases / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Scleritis / diagnosis
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Fluoroquinolones / therapeutic use. Humans. Intraocular Pressure. Lubricants / therapeutic use. Prednisolone / analogs & derivatives. Prednisolone / therapeutic use. Retinal Hemorrhage / diagnosis. Tropanes / therapeutic use

  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cornea. 1994 Jul;13(4):364-7 [7924339.001]
  • [Cites] Leuk Lymphoma. 1993 Sep;11(1-2):153-5 [8220151.001]
  • [Cites] Surv Ophthalmol. 2002 Nov-Dec;47(6):590-3 [12504742.001]
  • [Cites] Ophthalmology. 1983 Aug;90(8):899-905 [6195573.001]
  • [Cites] Am J Ophthalmol. 2002 Jul;134(1):141-2 [12095830.001]
  • [Cites] Turk J Pediatr. 1994 Jan-Mar;36(1):35-41 [8191606.001]
  • [Cites] Eye (Lond). 2004 Jul;18(7):663-72 [15002029.001]
  • (PMID = 18008055.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fluoroquinolones; 0 / Lubricants; 0 / Tropanes; 8B2807733D / prednisolone acetate; 8QS6WCL55Z / homatropine; 9PHQ9Y1OLM / Prednisolone; L4618BD7KJ / gatifloxacin
  •  go-up   go-down


18. Abdul-Rahim AS, Brown SM, Shami MJ: Bilateral retinal hemorrhages in an 18-year-old woman. Surv Ophthalmol; 2002 Nov-Dec;47(6):590-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A previously healthy 18-year-old woman presented with sudden onset of central blurred vision in the right eye.
  • Laboratory evaluation and subsequent bone marrow biopsy were consistent with the diagnosis of acute lymphoblastic leukemia.
  • The retinal findings had cleared almost completely by three weeks after initiation of chemotherapy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Hemorrhage / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Daunorubicin / therapeutic use. Diagnosis, Differential. Female. Humans. Papilledema / etiology. Prednisolone / therapeutic use. Treatment Outcome. Vincristine / therapeutic use. Visual Acuity

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504742.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; ZS7284E0ZP / Daunorubicin; DVP (daunomycin)
  •  go-up   go-down


19. Song WK, Min YH, Kim YR, Lee SC: Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab. Ophthalmology; 2008 Oct;115(10):1766-70
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
  • OBJECTIVE: To report on the clinical characteristics and treatment outcomes of cytomegalovirus (CMV) retinitis cases that occurred after allogeneic hematopoietic stem cell transplantation (HSCT) using an alemtuzumab-based (Campath-1H, Genzyme, Cambridge, MA) conditioning regimen.
  • PARTICIPANTS: Seven eyes of 4 patients in whom CMV retinitis developed after allogeneic HSCT using alemtuzumab.
  • CMV retinitis was diagnosed by the presence of characteristic ophthalmoscopic findings and confirmed by polymerase chain reaction-based detection of CMV in vitreal biopsy specimens.
  • The affected eyes received intravitreal injections of 2 mg/0.1 mL of ganciclovir twice weekly during induction therapy until the lesions were inactive, followed by weekly injections as maintenance therapy.
  • Maintenance intravitreal therapy continued until the lesions consisted of an atrophic retina with pigment epithelium mottling and attenuated vessels.
  • One patient died before initiation of treatment.
  • Patients underwent a mean of 8.3 intravitreal ganciclovir injections in each eye.
  • The treatment was well tolerated without serious adverse events during the mean follow-up period of 8.5 months (range, 4.5-16 months).
  • Intravitreal ganciclovir therapy seems to be an acceptable therapeutic option in these patients given the nature of their systemic illness, which prohibits the use of typical systemic anti-CMV drugs.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Antineoplastic Agents / adverse effects. Cytomegalovirus Retinitis / etiology. Hematopoietic Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antiviral Agents / therapeutic use. Combined Modality Therapy. Female. Ganciclovir / therapeutic use. Humans. Leukemia, Myeloid, Acute / drug therapy. Male. Postoperative Complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retrospective Studies. Transplantation, Homologous. Visual Acuity

  • Genetic Alliance. consumer health - Cytomegalovirus Retinitis.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthalmology. 2009 Apr;116(4):817-8; author reply 818-9 [19344836.001]
  • (PMID = 18562004.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 3A189DH42V / alemtuzumab; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


20. van Brussel M, Takken T, van der Net J, Engelbert RH, Bierings M, Schoenmakers MA, Helders PJ: Physical function and fitness in long-term survivors of childhood leukaemia. Pediatr Rehabil; 2006 Jul-Sep;9(3):267-74
MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the physical function and fitness in survivors of childhood leukaemia 5-6 years after cessation of chemotherapy.
  • MATERIALS AND METHODS: Thirteen children (six boys and seven girls; mean age 15.5 years) who were treated for leukaemia were studied 5-6 years after cessation of therapy.
  • RESULTS: On motor performance, seven of the 13 patients showed significant problems in the hand-eye co-ordination domain.
  • CONCLUSION: Even 5-6 years after cessation of childhood leukaemia treatment, there are still clear late effects on motor performance and physical fitness.
  • Chemotherapy-induced neuropathy and muscle atrophies are probably the prominent cause for these reduced test results.
  • [MeSH-major] Physical Fitness. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Survival

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050404.001).
  • [ISSN] 1363-8491
  • [Journal-full-title] Pediatric rehabilitation
  • [ISO-abbreviation] Pediatr Rehabil
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. al Lamki Z, Wali YA, Shah WM, Zachariah M: Relapsed acute leukemia in children: Oman experience. Pediatr Hematol Oncol; 2004 Mar;21(2):167-73
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It accounts for over one-third of all childhood cancers, most of which (approximately 75%) are acute lymphoblastic leukemia (ALL).
  • A retrospective review of case notes was used to study all children with a diagnosis of acute leukemia from January 1993 to January 2003.
  • They were classified as per BFM group as "very early," "early," and "late" according to the time from diagnosis to first relapse and were divided into isolated bone marrow (BM), extramedullary site, and combined relapse.
  • Most of the AML cases relapsed very early on in treatment.
  • Eleven patients had combined relapse in BM and extramedullary site (9 in the central nervous system, 1 in the testicles, and 1 in the eye).
  • [MeSH-minor] Acute Disease. Central Nervous System / pathology. Child. Child, Preschool. Eye / pathology. Female. Humans. Infant. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / mortality. Leukemia, Myeloid / pathology. Leukemic Infiltration. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Recurrence. Remission Induction / methods. Retrospective Studies. Testis / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15160516.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Russo V, Scott IU, Querques G, Stella A, Barone A, Delle Noci N: Orbital and ocular manifestations of acute childhood leukemia: clinical and statistical analysis of 180 patients. Eur J Ophthalmol; 2008 Jul-Aug;18(4):619-23
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate the association between presence of orbital or ocular lesions and type and stage of leukemia and to investigate whether orbital and ocular lesions are significant in predicting leukemia prognosis.
  • Lesions associated with leukemia may be classified as specific (due to leukemic infiltration of various ocular tissues), nonspecific (due to one of the secondary complications), or iatrogenic manifestations caused by chemotherapy.
  • Risk-based treatment assignment is based on clinical and laboratory features at diagnosis.
  • Children with presenting white blood cell count below 50,000 mm3 are considered at standard risk for treatment failure, while all others are considered at high risk for treatment failure.
  • [MeSH-major] Eye Neoplasms / pathology. Leukemia, Myeloid, Acute / pathology. Leukemic Infiltration / pathology. Orbital Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18609485.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Foroozan R: Ocular complications of sigmoid sinus thrombosis from L-asparaginase. J Pediatr Ophthalmol Strabismus; 2005 Mar-Apr;42(2):117-9
MedlinePlus Health Information. consumer health - Eye Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article presents a 9-year-old boy with acute lymphocytic leukemia who developed ocular complications after beginning treatment with L-asparaginase.
  • Symptoms gradually resolved after discontinuing L-asparaginase and treatment with heparin.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Asparaginase / adverse effects. Eye Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sinus Thrombosis, Intracranial / chemically induced. Sinus Thrombosis, Intracranial / complications
  • [MeSH-minor] Abducens Nerve. Child. Cranial Nerve Diseases / etiology. Esotropia / etiology. Fundus Oculi. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Papilledema / diagnosis. Papilledema / etiology

  • Genetic Alliance. consumer health - Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825749.001).
  • [ISSN] 0191-3913
  • [Journal-full-title] Journal of pediatric ophthalmology and strabismus
  • [ISO-abbreviation] J Pediatr Ophthalmol Strabismus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down






Advertisement